{
    "doi": "https://doi.org/10.1182/blood.V122.21.4953.4953",
    "article_title": "Correlation Between Clinical Features, CRLF2 Expression and Copy Number Alterations In Acute Lymphoblastic Leukemia ",
    "article_date": "November 15, 2013",
    "session_type": "611. Leukemias: Biology, Cytogenetics and Molecular Markers in Diagnosis and Prognosis",
    "abstract_text": "Background Acute lymphoblastic leukemia (ALL) is a heterogeneous disease comprising different genetic abnormalities. An increased cytokine receptor-like factor 2 (CRLF2) expression is associated with activating the JAK-STAT pathway and activation and leukemia initiation. Several studies have shown that some first events are insufficient to cause the development of ALL and other genetic changes are required. In 60% of cases, the altered genes are involved in lymphoid maturation (PAX, IKZF1, EBF, LEF1, BTALA/CD200, TOX), cell cycle control and tumour suppression (CDKN2A/B, PTEN, RB), or transcription factors and coactivators (ETV6, ERG, TBL1XR1). But the prognostic significance of deregulated CRLF2 mRNA expression in patients with CNA in the genes previously mentioned is not fully identified. Aims To analyze the frequency and prognostic significance of deregulated expression of \u00a0CRLF2 and the copy number alterations (CNA) in EBFF1, IKZF1, JAK2, CDKN, PAX, ETV, BTG1 and RB in a series of ALL patients enrolled in BFM, SHOP or PETHEMA clinical trials. Methods Bone Marrow samples at diagnosis from 69 ALL patients treated in Hospital Universitario 12 de Octubre, between January 2001 and December 2012, were studied by Multiplex ligation- dependent probe amplifications (MLPA) method was used to detect deletions or duplications of IKZF1, PAX5, ETV6, RB1, BTG1, EBF1 and CDKN2A-CDKN2B genes (SALSA MLPA kit P335-B1 ALL-IKZF1; MRC- Holland). Raw data was analyzed using Coffalyzer software (MRC-Holland) Results The median age was 22 years (0.9-88), 40 (58%) male and 29 (42%) female, median WBC count 70,753 x10 9 /L (1,000 \u2013 633,780). B-ALL subtype in 64 cases (92%) and T-ALL subtype in 5 cases (8%). Cytogenetics: 10 normal (14.5%), 16 hyperdiploid (20,5%), 8 t(9;22)(10.3%),4 cases 11q23/MLL (5.1%), and 24 (30.8%) with \u00a0other translocations or deletions and no growth (23.1%). \u00a0Cytogenetics risk was favourable in 25 cases (26.6%), intermediate in 10 cases (10.6%) and poor in 25 cases (26.6%). CRLF2 expression and CAN results are shown in table 1 . CRFL2 over expression was found in 18 cases (23%), it was associated with deletions of IKZF1 (p0.013). Deletions of CDNK were associated with T-ALL subtype (p0.049) and with a tendency to deletions TEL group (p0.081). Deletions of PAX were associated with JAK2 deletions (p0.027) and with a tendency to IKZF1 deletions (p0.064). Rb deletions were associated with ph+ ALL (p0.001) and it had a tendency to the risk of death. Other molecular alterations found were gains of gen EBF 2 (2.6%), IKZF 2 (2.6%), CDKN 4 (5.1%), PAX 5(6.4%), BTG\u00a0\u00a0 2 (2.6%), RB 2 (2.6%). There was no association between hyperdiploid karyotype and any of the gene gains analyzed. Regarding survival, CDKN deletions 2A/ B were associated with decreasing of progression free survival P (0.051), independent of the presence of Ph chromosome. Deletions of IKZF1 showed an increased risk of death (p0.011) and tendency for deletions of PAX (p0.064). Table 1  . . . CRFL . . IKARUS . . CDNK . . PAX . . RB .   No Overexpression  Overexpression  No deletion Deletion No deletion Deletion No deletion Deletion No deletion Deletion Age  < 10  18 11 23 3 17 9 20 6 22 3  10 a - 30 a  18 3 17 2 13 6 16 3 16 3  > 30  15 4 13 6 14 5 17 2 16 2  p   0,144  0,139  0,838  0,535  0,9 ALLsubtype  B  45 17 47 11 42 16 48 10 48 8  T  6 1 6 0 2 4 5 1 8 0  p   0,453  0,241  0,049   0,972  0,321 Cytogenetic  yes  7 3 9 0 5 4 8 1 7 2 normal  no  39 12 39 10 36 13 40 9 42 5  p   0,664  0,136  0,278  0,972  0,336 Ph + yes  5 1 4 2 5 1 4 2 2 3  no  0 14 44 8 36 16 44 8 47 4  p   0,635  0,27  0,472  0,27  0,001  Relapse  yes  13 5 15 2 10 7 16 1 14 3  no  35 12 35 9 33 11 34 10 38 4  p   0,854  0,429  0,214  0,125  0,382 Death  yes  16 6 15 6 13 8 16 5 16 5  no  33 11 36 5 31 10 35 6 36 3  p   0,842  0,11   0,261  0,371  0,08  IKZF1  No delection  43 10   36 17 46 7 45 7  Deletion  5 6   8 3 7 4 9 1  p   0,013     0,754  0,064   0,765 JAK2  No delection  48 15 52 11 44 19 53 10 54 7  Deletion  0 1 1 0 0 1 0 1 0 1  p   0,081   0,646  0,135  0,027   0,009  CDKN  No delection  34 10 36 8   37 7 37 5  Deletion  14 6 17 3   16 4 17 3  p   0,533  0,754    0,688  0,734 PAX  No delection  41 12 46 7 37 16   45 6  Deletion  7 4 7 4 7 4   9 2  p   0,339  0,064   0,688    0,565 TEL  No delection  40 13 44 9 34 19 45 8 43 8  Deletion  8 3 9 2 10 1 8 3 11 0  p   0,848  0,923  0,081   0,33  0,139 . . . CRFL . . IKARUS . . CDNK . . PAX . . RB .   No Overexpression  Overexpression  No deletion Deletion No deletion Deletion No deletion Deletion No deletion Deletion Age  < 10  18 11 23 3 17 9 20 6 22 3  10 a - 30 a  18 3 17 2 13 6 16 3 16 3  > 30  15 4 13 6 14 5 17 2 16 2  p   0,144  0,139  0,838  0,535  0,9 ALLsubtype  B  45 17 47 11 42 16 48 10 48 8  T  6 1 6 0 2 4 5 1 8 0  p   0,453  0,241  0,049   0,972  0,321 Cytogenetic  yes  7 3 9 0 5 4 8 1 7 2 normal  no  39 12 39 10 36 13 40 9 42 5  p   0,664  0,136  0,278  0,972  0,336 Ph + yes  5 1 4 2 5 1 4 2 2 3  no  0 14 44 8 36 16 44 8 47 4  p   0,635  0,27  0,472  0,27  0,001  Relapse  yes  13 5 15 2 10 7 16 1 14 3  no  35 12 35 9 33 11 34 10 38 4  p   0,854  0,429  0,214  0,125  0,382 Death  yes  16 6 15 6 13 8 16 5 16 5  no  33 11 36 5 31 10 35 6 36 3  p   0,842  0,11   0,261  0,371  0,08  IKZF1  No delection  43 10   36 17 46 7 45 7  Deletion  5 6   8 3 7 4 9 1  p   0,013     0,754  0,064   0,765 JAK2  No delection  48 15 52 11 44 19 53 10 54 7  Deletion  0 1 1 0 0 1 0 1 0 1  p   0,081   0,646  0,135  0,027   0,009  CDKN  No delection  34 10 36 8   37 7 37 5  Deletion  14 6 17 3   16 4 17 3  p   0,533  0,754    0,688  0,734 PAX  No delection  41 12 46 7 37 16   45 6  Deletion  7 4 7 4 7 4   9 2  p   0,339  0,064   0,688    0,565 TEL  No delection  40 13 44 9 34 19 45 8 43 8  Deletion  8 3 9 2 10 1 8 3 11 0  p   0,848  0,923  0,081   0,33  0,139 View Large Conclusions Our findings are consistent with those of other published series. CDKN deletions 2A / B were associated with a decreased progression free survival, independent of the presence of Ph chromosome as described in other series. RB deletions are associated with ph + and have not been described previously, but these findings must be confirm with additional studies. Disclosures: No relevant conflicts of interest to declare.",
    "topics": [
        "acute lymphocytic leukemia",
        "burkitt's lymphoma",
        "signs and symptoms",
        "adult t-cell lymphoma/leukemia",
        "magnetic resonance cholangiography",
        "protein p16",
        "t-cell leukemia, acute",
        "bone marrow specimen",
        "cytokine",
        "karyotype determination procedure"
    ],
    "author_names": [
        "Juan Carlos Ponce Jarquin",
        "Rosa M. Ayala, MD, PhD",
        "Ana Belen Due\u00f1as Perez, MD, PhD",
        "Daniel Rueda",
        "Mar\u00eda Luisa Martin Ramos",
        "Jos\u00e9 Luis Vivanco, MD, PhD",
        "Pilar Martinez S\u00e1nchez, MD, PhD",
        "Rafael Alberto Alonso Fernandez",
        "Florinda Gilsanz Rodriguez",
        "Joaquin Martinez -Lopez"
    ],
    "author_dict_list": [
        {
            "author_name": "Juan Carlos Ponce Jarquin",
            "author_affiliations": [
                "Hematology, Hospital Universitario 12 de Octubre, Madrid, Spain, "
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Rosa M. Ayala, MD, PhD",
            "author_affiliations": [
                "Hematology, Hospital Universitario 12 de Octubre, Madrid, Spain, "
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Ana Belen Due\u00f1as Perez, MD, PhD",
            "author_affiliations": [
                "Hematology, Hospital Universitario 12 de Octubre, Madrid, Spain, "
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Daniel Rueda",
            "author_affiliations": [
                "Molecular Biology, Hospital universitario 12 de Octubre, madrid, Spain, "
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Mar\u00eda Luisa Martin Ramos",
            "author_affiliations": [
                "Genetic, Hospital Universitario 12 de Octubre, Madrid, Spain, "
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Jos\u00e9 Luis Vivanco, MD, PhD",
            "author_affiliations": [
                "Pediatric, Hospital Doce de Octubre, Madrid, Spain, "
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Pilar Martinez S\u00e1nchez, MD, PhD",
            "author_affiliations": [
                "Hematology, Hospital Universitario 12 de Octubre, Madrid, Spain, "
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Rafael Alberto Alonso Fernandez",
            "author_affiliations": [
                "Hematology, Hospital Universitario 12 de Octubre, Madrid, Spain, "
            ],
            "author_rank": 8,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Florinda Gilsanz Rodriguez",
            "author_affiliations": [
                "Hematology, Hospital Universitario 12 de Octubre, Madrid, Spain, "
            ],
            "author_rank": 9,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Joaquin Martinez -Lopez",
            "author_affiliations": [
                "Hematology, H Universitario 12 de Octubre, Madrid, Spain"
            ],
            "author_rank": 10,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-05-26T18:45:48",
    "is_scraped": "1"
}